Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE9A | O76083 | 19/20 | 1.00 |
| ▸ | PDE1C | Q14123 | 3/20 | 0.53 |
| ▸ | CDK4 | P11802 | 1/20 | 0.43 |
| ▸ | CCND1 | P24385 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8311051 | 0.92 | PDE9A (0.85) | PDE9APDE1CCDK4CCND1 | |
| SCHEMBL10116335 | 0.90 | PDE9A (0.82) | PDE9APDE1CCDK4CCND1 | |
| SCHEMBL10116375 | 0.88 | PDE9A (0.79) | PDE9APDE1CCDK4CCND1 | |
| SCHEMBL10116249 | 0.85 | PDE9A (0.74) | PDE9APDE1CCDK4CCND1 | |
| SCHEMBL8306675 | 0.84 | PDE9A (0.73) | PDE9APDE1C | |
| SCHEMBL8307144 | 0.84 | PDE9A (0.73) | PDE9APDE1CCDK4CCND1 | |
| SCHEMBL1456761 | 0.83 | PDE9A (0.71) | PDE9APDE1CCDK4CCND1 | |
| SCHEMBL10116371 | 0.82 | PDE9A (0.69) | PDE9APDE1CCDK4CCND1 | |
| SCHEMBL10116368 | 0.81 | PDE9A (0.68) | PDE9APDE1CCDK4CCND1 | |
| SCHEMBL18791284 | 0.80 | PDE9A (0.78) | PDE9APDE1C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2017070293-A1 | PHOSPHODIESTERASE 9 INHIBITOR AND LEVODOPA THERAPY | IRONWOOD PHARMACEUTICALS, INC. (US) | 2017-04-27 | — | — | WO | disclosed |
| US-8822479-B2 | 6-cyclylmethyl-and 6-alkylmethyl-substituted pyrazolepyrimidines | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-09-02 | — | — | US | disclosed |
| US-8822479-B2 | 6-cyclylmethyl-and 6-alkylmethyl-substituted pyrazolepyrimidines | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-09-02 | — | — | US | disclosed |
| US-8822479-B2 | 6-cyclylmethyl-and 6-alkylmethyl-substituted pyrazolepyrimidines | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-09-02 | — | — | US | disclosed |
| US-8642605-B2 | 6-cyclylmethyl-and 6-alkylmethyl-substituted pyrazolepyrimidines | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-02-04 | — | — | US | disclosed |
| EP-2298773-B1 | 6-Cyclomethyl and 6-alkylmethyl substituted pyrazolopyrimidines | BOEHRINGER INGELHEIM INT (DE) | 2013-06-19 | — | — | EP | disclosed |
| EP-2298773-B1 | 6-Cyclomethyl and 6-alkylmethyl substituted pyrazolopyrimidines | BOEHRINGER INGELHEIM INT (DE) | 2013-06-19 | — | — | EP | disclosed |
| US-20120010224-A1 | 6-CYCLYLMETHYL-AND 6-ALKYLMETHYL-SUBSTITUTED PYRAZOLEPYRIMIDINES | HENDRIX MARTIN (DE) | 2012-01-12 | — | — | US | disclosed |
| US-20120010224-A1 | 6-CYCLYLMETHYL-AND 6-ALKYLMETHYL-SUBSTITUTED PYRAZOLEPYRIMIDINES | HENDRIX MARTIN (DE) | 2012-01-12 | — | — | US | disclosed |
| US-20120010224-A1 | 6-CYCLYLMETHYL-AND 6-ALKYLMETHYL-SUBSTITUTED PYRAZOLEPYRIMIDINES | HENDRIX MARTIN (DE) | 2012-01-12 | — | — | US | disclosed |
| US-8044060-B2 | 6-cyclylmethyl- and 6-alkylmethyl pyrazolo[3,4-D]pyrimidines, methods for their preparation and methods for their use to treat impairments of perception, concentration learning and/or memory | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-10-25 | — | — | US | disclosed |
| US-8044060-B2 | 6-cyclylmethyl- and 6-alkylmethyl pyrazolo[3,4-D]pyrimidines, methods for their preparation and methods for their use to treat impairments of perception, concentration learning and/or memory | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-10-25 | — | — | US | disclosed |
| EP-1626971-B1 | 6-CYCLYLMETHYL- AND 6-ALKYLMETHYL-SUBSTITUTED PYRAZOLOPYRIMIDINES | BOEHRINGER INGELHEIM INT (DE) | 2011-08-10 | — | — | EP | disclosed |
| EP-1626971-B1 | 6-CYCLYLMETHYL- AND 6-ALKYLMETHYL-SUBSTITUTED PYRAZOLOPYRIMIDINES | BOEHRINGER INGELHEIM INT (DE) | 2011-08-10 | — | — | EP | disclosed |
| EP-2298773-A1 | 6-Cyclomethyl and 6-alkylmethyl substituted pyrazolopyrimidines | Boehringer Ingelheim International GmbH (DE) | 2011-03-23 | — | — | EP | disclosed |
| EP-2298773-A1 | 6-Cyclomethyl and 6-alkylmethyl substituted pyrazolopyrimidines | Boehringer Ingelheim International GmbH (DE) | 2011-03-23 | — | — | EP | disclosed |
| US-20110065730-A1 | 6-CYCLYLMETHYL-AND 6-ALKYLMETHYL-SUBSTITUTED PYRAZOLEPYRIMIDINES | HENDRIX MARTIN | 2011-03-17 | — | — | US | disclosed |
| US-20070105876-A1 | 6-Cyclylmethyl- and 6-alkylmethyl-substituted pyrazolepyrimidines | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-05-10 | — | — | US | disclosed |
| EP-1626971-A1 | 6-CYCLYLMETHYL- AND 6-ALKYLMETHYL-SUBSTITUTED PYRAZOLOPYRIMIDINES | Bayer HealthCare AG (DE) | 2006-02-22 | — | — | EP | disclosed |
| WO-2004099211-A1 | 6-CYCLYLMETHYL- AND 6-ALKYLMETHYL-SUBSTITUTED PYRAZOLOPYRIMIDINES | BAYER HEALTHCARE AG (DE) | 2004-11-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110065730-A1 | 6-CYCLYLMETHYL-AND 6-ALKYLMETHYL-SUBSTITUTED PYRAZOLEPYRIMIDINES | GRM6, P2RX6, P2RY6 | PDE9A 384/4885PDE1C 464/4885CDK4 181/4885 |
| US-20070105876-A1 | 6-Cyclylmethyl- and 6-alkylmethyl-substituted pyrazolepyrimidines | GRM6, P2RX6, P2RY6 | PDE9A 384/4885PDE1C 464/4885CDK4 181/4885 |
| US-20120010224-A1 | 6-CYCLYLMETHYL-AND 6-ALKYLMETHYL-SUBSTITUTED PYRAZOLEPYRIMIDINES | GRM6, P2RX6, P2RY6 | PDE9A 384/4885PDE1C 464/4885CDK4 181/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.